Jazzpharma
Bookmark
ShareCopied to clipboardJazzpharma is a company. It is a public company in Dublin, Ireland. It was founded in 2003 and its current CEO is Bruce C. Cozadd. It is part of the Health Care sector, specifically in the Biotechnology industry.
Key facts
- city: Dublin
- country: Ireland
- employees: 2,800 people
- revenues: 4.1B $
- company type: public
- sector: Health Care
- industry: Biotechnology
- foundation year: 2003
- CEO: Bruce C. Cozadd
- CEO approval: 68 %
- ESG score: Try Pro to see estimate
See more facts
Extract data
Download datasets about Jazzpharma:
Dataset of stocks from Jazzpharma:
Jazzpharma is one of the companies in Ireland, companies in Biotechnology, companies in Health Care, companies in Dublin and 3,456,808 companies in our database.
Talking Points
- Improving Patients' Lives | Jazz Pharmaceuticals
- Jazz Pharmaceuticals is focused on improving patients’ lives by identifying, developing, and commercializing products that address unmet medical needs.
- We’re a global biopharma company developing life-changing medicines for people with limited or no options. Please see our social guidelines - https://t.co/ny1WC5R7Gb
- Jazz Pharmaceuticals plc (Nasdaq: JAZZ), is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are focused on developing life-changing medicines for people with serious diseases—often with limited or no options—so they can live their lives more fully.
- Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
- Jazz Pharmaceuticals Careers
- Villa Guardia, Italy (Gentium S.r.l) | Jazz Pharmaceuticals
- Villa Guardia, Italy (Gentium S.r.I.) Gentium S.r.l. is a Jazz Pharmaceuticals company. Located in Villa Guardia, Italy, Gentium’s manufacturing plant and QC laboratories supply active pharmaceutical ingredients (API) to Jazz and various other pharmaceutical companies around the world. Medical and sales support for Jazz’s products in Italy is provided by Jazz Healthcare Italy S.r.l. With